PMU80 DETERMINING THE EPIDEMIOLOGY, PATIENT FLOW, TREATMENT AND UNMET NEEDS OF PATIENTS WITH CHRONIC LIVER DISEASE-ASSOCIATED SEVERE THROMBOCYTOPENIA UNDERGOING INVASIVE PROCEDURES IN SPAIN

Abstract Background Chronic liver disease (CLD) is often complicated by severe thrombocytopenia (platelet count < 50,000/µL). Platelet transfusion has been a gold standard for increasing the platelet count to prevent hemorrhagic events in such patients. Lusutrombopag, a thrombopoietin receptor agonist, can increase the platelet count in such patients when invasive procedures are scheduled. Former studies on lusutrombopag included patients with a platelet count of > 50,000/µL at baseline: the proportions of patients who did not require platelet transfusion were 84–96%, which might be overestimated. Methods The efficacy and safety of lusutrombopag were retrospectively investigated in CLD patients with platelet count of < 50,000/µL, a criterion for platelet transfusion, in real-world settings. We examined the proportion of patients who did not require platelet transfusion in 31 CLD patients, which exceeded a minimum required sample size (21 patients) calculated by 80% power at a significance level of 5%. Lusutrombopag, 3 mg once daily, was administered 8–18 days before scheduled invasive procedures. Results Among 31 patients who received lusutrombopag, 23 patients (74.2%) patients showed a platelet count of ≥ 50,000/µL (Group A) and did not require platelet transfusion. The remaining 8 patients (25.8%) did not reached platelet ≥ 50,000/µL (Group B). The means of platelet increase were 38,000/µL and 12,000/µL in groups A and B, respectively. A low platelet count at baseline was a characteristic of patients in group B. Among 13 patients who repeatedly used lusutrombopag, lusutrombopag significantly increased the platelet count as the initial treatment. When all repeated uses of lusutrombopag were counted among these 13 patients, platelet transfusion was not required in 82.1% (23/28) of treatments. Although one patient showed portal thrombosis after lusutrombopag treatment, the thrombosis was disappeared by anticoagulant treatment for 35 days. The degree of platelet increase with lusutrombopag was larger than that in their previous platelet transfusion. Conclusions The proportion of patients who did not require platelet transfusion was 74.2%, which is smaller than that in former studies which included CLD patients with a platelet count of > 50,000/µL. However, lusutrombopag is effective and safe for CLD patients with a platelet count of < 50,000/µL.

Download Full-text

PDB34 Comparative Efficacy and Safety of Avatrombopag Versus Lusutrombopag in Patients with Chronic LIVER Disease and Severe Thrombocytopenia Undergoing Invasive Procedures: A Systematic Literature Review and Network Meta-Analysis

Value in Health ◽

10.1016/j.jval.2021.04.431 ◽

2021 ◽

Vol 24 ◽

pp. S84

Author(s):

P. Wojciechowski ◽

K. Wilson ◽

M. Pochopień ◽

I. Pustulka ◽

B. Smela ◽

...

Keyword(s):

Liver Disease ◽

Literature Review ◽

Chronic Liver Disease ◽

Systematic Literature Review ◽

Meta Analysis ◽

Chronic Liver ◽

Severe Thrombocytopenia ◽

Efficacy And Safety ◽

Invasive Procedures ◽

Comparative Efficacy

Download Full-text

Lusutrombopag is Effective and Safe in Patients with Chronic Liver Disease and Severe Thrombocytopenia: A Multicenter Retrospective Study

10.21203/rs.3.rs-79320/v1 ◽

2020 ◽

Author(s):

Hiroaki Nomoto ◽

Naoki Morimoto ◽

Kouichi Miura ◽

Shunji Watanabe ◽

Yoshinari Takaoka ◽

...

Keyword(s):

Platelet Count ◽

Liver Disease ◽

Chronic Liver Disease ◽

Platelet Transfusion ◽

Chronic Liver ◽

Severe Thrombocytopenia ◽

Invasive Procedures ◽

Group A ◽

Low Platelet Count ◽

Group B

Abstract Background: Chronic liver disease (CLD) is often complicated by severe thrombocytopenia (platelet count <50,000/µL). Platelet transfusion has been a gold standard for increasing the platelet count to prevent hemorrhagic events in such patients. Lusutrombopag, a thrombopoietin receptor agonist, can increase the platelet count in such patients when invasive procedures are scheduled. However, we have little information on the effect of lusutrombopag in CLD patients with severe thrombocytopenia in real-world settings.Methods: To investigate the efficacy and safety of lusutrombopag in patients with chronic liver disease and severe thrombocytopenia, we retrospectively investigated 26 CLD patients with a platelet count of <50,000/µL. Lusutrombopag, 3 mg once daily, was administered 8-15 days before scheduled invasive procedures.Results: Among 26 patients who received lusutrombopag, 19 patients (73.1%) patients showed a platelet count of ≥50,000/µL (Group A) and did not require platelet transfusion. The remaining 7 patients (26.9%) did not reached platelet ≥50,000/µL (Group B). The means of platelet increase were 36,000/µL and 13,000/µL in groups A and B, respectively. A low platelet count at baseline was a characteristic of patients in group B. Among 13 patients who repeatedly used lusutrombopag, lusutrombopag significantly increased the platelet count as the initial treatment. No adverse events were noted during or after lusutrombopag treatment. In addition, the degree of platelet increase with lusutrombopag was larger than that in their previous platelet transfusion.Conclusions: Lusutrombopag is effective and safe for CLD patients with a platelet count of <50,000/µL.

Download Full-text

Lusutrombopag for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures

American Journal of Therapeutics ◽

10.1097/mjt.0000000000001356 ◽

2021 ◽

Vol Publish Ahead of Print ◽

Author(s):

Azizullah Beran ◽

Sami Ghazaleh ◽

Mohammed Mhanna ◽

Omar Srour ◽

Justin Chuang ◽

...

Keyword(s):

Liver Disease ◽

Chronic Liver Disease ◽

Chronic Liver ◽

Invasive Procedures

Download Full-text

Primary Hemostasis in Chronic Liver Disease and Cirrhosis: What Did We Learn over the Past Decade?

International Journal of Molecular Sciences ◽

10.3390/ijms21093294 ◽

2020 ◽

Vol 21 (9) ◽

pp. 3294

Author(s):

Marie-Astrid van Dievoet ◽

Stéphane Eeckhoudt ◽

Xavier Stephenne

Keyword(s):

Liver Disease ◽

Chronic Liver Disease ◽

Portal Pressure ◽

Chronic Liver ◽

Hemorrhagic Complication ◽

Invasive Procedures ◽

The Past ◽

Primary Hemostasis ◽

Thrombotic Complications ◽

Von Willebrand

Changes in primary hemostasis have been described in patients with chronic liver disease (CLD) and cirrhosis and are still subject to ongoing debate. Thrombocytopenia is common and multifactorial. Numerous studies also reported platelet dysfunction. In spite of these changes, primary hemostasis seems to be balanced. Patients with CLD and cirrhosis can suffer from both hemorrhagic and thrombotic complications. Variceal bleeding is the major hemorrhagic complication and is mainly determined by high portal pressure. Non portal hypertension-related bleeding due to hemostatic failure is uncommon. Thrombocytopenia can complicate management of invasive procedures in CLD patients. Recently, oral thrombopoietin agonists have been approved to raise platelets before invasive procedures. In this review we aim to bundle literature, published over the past decade, discussing primary hemostasis in CLD and cirrhosis including (1) platelet count and the role of thrombopoietin (TPO) agonists, (2) platelet function tests and markers of platelet activation, (3) von Willebrand factor and (4) global hemostasis tests.

Download Full-text

Thrombopoietin Receptor Agonists in Patients with Chronic Liver Disease

Seminars in Thrombosis and Hemostasis ◽

10.1055/s-0040-1715451 ◽

2020 ◽

Vol 46 (06) ◽

pp. 682-692

Author(s):

Saro Khemichian ◽

Norah A. Terrault

Keyword(s):

Liver Disease ◽

Chronic Liver Disease ◽

Invasive Procedure ◽

Bleeding Risk ◽

Chronic Liver ◽

Bleeding Complications ◽

Invasive Procedures ◽

Platelet Counts ◽

Receptor Agonists ◽

Platelet Transfusions

AbstractThrombocytopenia is one of the most common hematologic complications in cirrhosis. Despite limited data linking platelet count and bleeding risk in patients with cirrhosis, the use of platelets transfusions for invasive procedures has been a common practice. Recently, thrombopoietin (TPO) receptor agonists have been approved for use in patients with chronic liver disease (CLD) undergoing invasive procedures. The aim of this study was to review current literature on bleeding risk in patients with cirrhosis and the use of platelet transfusions and TPO receptor agonists in the context of invasive procedures. PubMed search was conducted to find articles relating to cirrhosis, thrombocytopenia, and new novel treatments for this condition. Search terms included CLD, cirrhosis, thrombocytopenia, bleeding, thrombosis, coagulopathy, hemostasis, and TPO receptor agonists. Romiplostim, eltrombopag, avatrombopag, and lusutrombopag are approved TPO receptor agonists, with avatrombopag and lusutrombopag specifically approved for use in patients with CLD undergoing invasive procedures. In patients with platelet counts < 50,000/mm3, avatrombopag and lusutrombopag increased the platelet counts above this threshold in the majority of treated patients and reduced the frequency of platelet transfusions. At the approved doses, incidence of thrombosis was not increased and therapies were well tolerated. Studies were not powered to assess whether risk of bleeding complications was reduced and the fundamental question of whether correction of thrombocytopenia is warranted in patients undergoing invasive procedures remains unanswered. The use of TPO receptor agonists has resulted in less requirement for platelet transfusions. In patients with cirrhosis undergoing invasive procedures for whom platelet transfusion is planned, TPO receptor agonists are an alternative and avoid the risks associated with transfusions. However, there is need for a thoughtful approach to manage bleeding risk in patients with cirrhosis undergoing procedures, with the consideration of a comprehensive hemostatic profile, the severity of portal hypertension, and the complexity of the invasive procedure to guide decisions regarding transfusions or use of TPO receptor agonists.

Download Full-text